IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $20.00 | Buy | Lake Street |
| 1/7/2025 | $15.00 | Buy | TD Cowen |
| 1/7/2025 | $9.00 | Overweight | Cantor Fitzgerald |
| 1/7/2025 | $22.00 | Overweight | Barclays |
Fastest customizable press release news feed in the world
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the "PARADIGM Trial"). The procedures were performed by Prof. Dr. Ole De Backer at, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. "We a
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT® 2025 – The 37th Annual Transcatheter Cardiovascular Therapeutics® Conference, taking place in San Francisco, California, October 25-28, 2025. An oral presentation is scheduled for Monday, October 27 (2:27pm GMT-7) in the Innovation Theater, Ha
MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the "PARADIGM Trial"). Patient recruitment at Danish centers is expected to begin in 4Q 2025. PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of
MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the "Special Meeting") virtually on Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 19, 2025), the Company adjourned the Special Meeting until Monday, September 29, 2025 at 8:00 a.m. Central time (being 11:00 p.m. AEST on Monday, September 29, 2025). The Company
MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the "Special Meeting"), which was originally scheduled to be held on Thursday, September 11, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 12, 2025), has been postponed. The Special Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/AVR2025SM, on Thur
MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the "Special Meeting"), which was originally scheduled to be held on Thursday, September 4, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 5, 2025), has been postponed. The Special Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/AVR2025SM, on Thursd
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 Highlights 130 patients implanted with the DurAVR® THV since the start of clinical development; 49 patients treated year-to-date; 21 in the quarterWorld first "double DurAVR®" implant in a patient receiving a valve-in-valve replacement in both the mitral and ao
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o
MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights Investigational Device Exemption ("IDE") for the DurAVR® THV's global, pivotal clinical trial (the "PARADIGM Trial"), submitted to the FDA during the First QuarterScale up for commencement of the PARADIGM Trial ongoing – including expanding the Clinical S
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic stenosis. Highlights: Over 100 patients successfully treated with the DurAVR® THV,
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00
TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00
Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00
Barclays initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $22.00
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
DEFA14A - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
DEFA14A - Anteris Technologies Global Corp. (0002011514) (Filer)
8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
DEFA14A - Anteris Technologies Global Corp. (0002011514) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)
4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)
4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)
4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
Live Leadership Updates
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o